BioSpace News Archive

Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $11 million in new capital from sales of its holdings of marketable securities, including shares of OncoCyte Corporation (Nasdaq: OCX)

Business leaders and community organizations have joined forces to support R.E.S.T., “Reopening Effectively and Safely Together”, a multi-state mission and initiative created and designed to address the tough challenges ahead as we look forward to the post-COVID-19 world.

ABU DHABI, United Arab Emirates--( BUSINESS WIRE )-- Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202103080

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33rd Annual Roth Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE™) for cancer, announces preclinical results for its ROR1 TriKE™ product candidate as a prospective therapy for the treatment of prostate cancer.

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that it has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration seeking approval to begin a U.S. pivotal trial for the VenoValve®.

Apollo Endosurgery, Inc. (NASDAQ:APEN) , a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the assignment of Category I Current Procedural Terminology codes with short form descriptor esophagogastroduodenoscopy with deployment of gastric bariatric device (e.g., balloon) under endoscopic guidance.

Skye Bioscience, Inc., a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board.